Uhm Sunho, Cho Yoon Ah, Choe Ji-Young, Park Ji Won, Kim Min-Jeong, Han Won-Ho, Lee Junyong, Lee Jung Woo, Shin Dong Woo, Soh Jae Seung, Lim Hyun, Kang Ho Suk, Moon Sung-Hoon, Kim Sung-Eun
Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea.
Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea.
Diagnostics (Basel). 2023 Feb 10;13(4):659. doi: 10.3390/diagnostics13040659.
Peptidyl arginine deiminases (PAD) enzymes have been investigated in various cancers. Recently, PAD enzyme, in particular PAD2, has been further implicated in cancers. Although the expression of PAD2 was significantly higher in hepatocellular carcinoma (HCC) tissue, its diagnostic or prognostic role of PAD2 in HCC patients is unknown. This study investigated whether the expression of PAD2 affects recurrence and survival in HCC patients who underwent hepatic resection. One hundred and twenty-two HCC patients after hepatic resection were enrolled. The median follow-up was 41 months (range 1-213 months) in enrolled patients. To investigate an association between PAD2 expression level and the clinical characteristics of enrolled patients, the recurrence of HCC following surgical resection and survival of the patients were examined. Ninety-eight cases (80.3%) of HCC demonstrated a higher expression of PAD2. The expression of PAD2 was correlated with age, hepatitis B virus positivity, hypertension, and higher alpha-fetoprotein level. There was no association between PAD2 expression and sex, diabetes mellitus, Child-Pugh class, major portal vein invasion, HCC size or number. The recurrence rates in patients with lower PAD2 expression were higher than those with higher PAD2 expression. The cumulative survival rates of patients with higher PAD2 expression were better than those of patients with lower PAD2 expression, but it was not statistically significant. In conclusion, PAD2 expression is closely associated with recurrence of HCC patients following surgical resection.
肽基精氨酸脱亚氨酶（PAD）已在多种癌症中得到研究。最近，PAD酶，尤其是PAD2，在癌症中被进一步认为有牵连。尽管PAD2在肝细胞癌（HCC）组织中的表达明显更高，但其在HCC患者中的诊断或预后作用尚不清楚。本研究调查了PAD2的表达是否会影响接受肝切除的HCC患者的复发和生存情况。招募了122例肝切除术后的HCC患者。纳入患者的中位随访时间为41个月（范围1 - 213个月）。为了研究PAD2表达水平与纳入患者临床特征之间的关联，检查了手术切除后HCC的复发情况以及患者的生存情况。98例（80.3%）HCC病例显示PAD2表达较高。PAD2的表达与年龄、乙肝病毒阳性、高血压以及较高的甲胎蛋白水平相关。PAD2表达与性别、糖尿病、Child-Pugh分级、主要门静脉侵犯、HCC大小或数量之间无关联。PAD2表达较低的患者复发率高于PAD2表达较高的患者。PAD2表达较高的患者累积生存率优于PAD2表达较低的患者，但差异无统计学意义。总之，PAD2表达与手术切除后HCC患者的复发密切相关。
